News
CLLS
1.380
+24.32%
0.270
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 22h ago
Cellectis to Report Third-Quarter 2026 Results on Nov. 12
TipRanks · 2d ago
Weekly Report: what happened at CLLS last week (1102-1106)?
Weekly Report · 3d ago
Weekly Report: what happened at CLLS last week (1026-1030)?
Weekly Report · 11/02 09:32
Cellectis S.A. Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026
NASDAQ · 10/28 11:13
Cellectis Showcases Strong Preclinical Data for APOC3 Base Editor .HEAL-101 at ESGCT 2026
TipRanks · 10/28 10:38
Cellectis' .HEAL-101 Lowers Triglycerides In Preclinical Study; Phase 1 Data Expected In H2'27
NASDAQ · 10/28 10:33
Cellectis sees FY27 adjusted EPS $21.50
TipRanks · 10/26 20:50
Cellectis sees FY27 capital expenditures $1.5B-$2B
TipRanks · 10/26 20:50
Cellectis sees Q4 adjusted EPS $3.37-$3.57
TipRanks · 10/26 20:45
Cellectis raises FY26 adjusted EPS view to $11.55 from $11.30, consensus $11.15
TipRanks · 10/26 20:45
Weekly Report: what happened at CLLS last week (1019-1023)?
Weekly Report · 10/26 09:32
Weekly Report: what happened at CLLS last week (1012-1016)?
Weekly Report · 10/19 09:32
Weekly Report: what happened at CLLS last week (1005-1009)?
Weekly Report · 10/12 09:34
Monthly information on share capital and company voting rights
Barchart · 10/06 15:30
Weekly Report: what happened at CLLS last week (0928-1002)?
Weekly Report · 10/05 09:34
Weekly Report: what happened at CLLS last week (0921-0925)?
Weekly Report · 09/28 09:32
Weekly Report: what happened at CLLS last week (0914-0918)?
Weekly Report · 09/21 09:32
CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law
Barchart · 09/19 18:31
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Barchart · 09/17 10:00
More
Webull provides a variety of real-time CLLS stock news. You can receive the latest news about Cellectis through multiple platforms. This information may help you make smarter investment decisions.
About CLLS
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.